POSANOL 300 MG / 16.7 ML
POSACONAZOLE : 300 MG / 16.7 ML · DIN 02432676 · MERCK CANADA INC
Health Canada status: MARKETED
What is POSANOL?
POSANOL 300 MG / 16.7 ML contains POSACONAZOLE : 300 MG / 16.7 ML. It is listed in the Health Canada Drug Product Database under DIN 02432676, held by MERCK CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 24-Nov-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is POSANOL used for?
Prophylaxis of Aspergillus and Candida infections in high-risk patients; Treatment of invasive aspergillosis refractory to or intolerant of amphotericin B or itraconazole; OPC (Suspension only).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02432676 |
|---|---|
| Brand name | POSANOL |
| Generic / active ingredient | POSACONAZOLE : 300 MG / 16.7 ML |
| Manufacturer | MERCK CANADA INC |
| Strength | 300 MG / 16.7 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J02AC04 POSACONAZOLE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Nov-2014 |
How is it administered?
IV: 300mg BID day 1, then 300mg QD. Tablets: 300mg BID day 1, then 300mg QD. Suspension: Prophylaxis 200mg TID; Treatment 400mg BID. Tablets/Suspension are NOT interchangeable.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Injection: Refrigerated 2-8°C. Admixture: Use immediately or store up to 24h at 2-8°C. (General storage for tablets/suspension not fully detailed in provided snippet).
How is it supplied?
Injection: 16.7 mL Type I glass vials. Tablets: 60 count HDPE bottles. Suspension: 105 mL amber glass bottles with measuring spoon.
Contraindications
Hypersensitivity to posaconazole or other azoles; Co-administration with ergot alkaloids, sirolimus, or CYP3A4 substrates (terfenadine, astemizole, cisapride, pimozide, quinidine) and statins.
Warnings and precautions
Serious drug interactions; Cardiovascular effects (QT prolongation); Hepatic toxicity. Tablets and Oral Suspension are not interchangeable. Contains glucose (Suspension).
What can be used instead?
Other Canadian products sharing ATC code J02AC04 POSACONAZOLE. 8 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| GLN-POSACONAZOLE | 100 MG | TABLET (DELAYED-RELEASE) | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | DIN 02542021 |
| JAMP POSACONAZOLE | 40 MG | SUSPENSION | JAMP PHARMA CORPORATION | MARKETED | DIN 02530333 |
| MINT-POSACONAZOLE | 100 MG | TABLET (DELAYED-RELEASE) | MINT PHARMACEUTICALS INC | MARKETED | DIN 02544644 |
| POSANOL | 100 MG | TABLET (DELAYED-RELEASE) | MERCK CANADA INC | MARKETED | DIN 02424622 |
| POSANOL | 200 MG / 5 ML | SUSPENSION | MERCK CANADA INC | MARKETED | DIN 02293404 |
| SANDOZ POSACONAZOLE | 100 MG | TABLET (DELAYED-RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02496259 |
| TARO-POSACONAZOLE | 100 MG | TABLET (DELAYED-RELEASE) | TARO PHARMACEUTICALS INC | MARKETED | DIN 02543311 |
| APO-POSACONAZOLE | 100 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | APPROVED | DIN 02511878 |
Who else supplies POSACONAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. POSACONAZOLE appears in 106 registered pack listings across 12 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.